LMND

ANALYST NOTE: LEMONADE, INC. (LMND) DATE: 2026-06-13

1. Structural Readiness

Current Price: $58.84 Conservative Entry: — (Not yet actionable; requires breakout confirmation) Aggressive Entry: $69.83 (Pre-breakout / forming entry) Breakout Level: $99.90 (Resistance level that must be cleared to confirm the setup) Extension: —

Classification: The setup is classified as FORMING.

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Macro Context: There is no named secular thesis attached to this name as of 2026-06-13. This is not a macro-driven play but a tactical, setup-led opportunity. Judgment Criteria: Conviction must be derived strictly from the quality of the structural setup (the Coil formation) and the underlying business fundamentals reported in the most recent filings. No external narrative or "story" should be invented to justify the position; the trade is valid only if the structure holds and the business metrics support the valuation.

3. Business Fundamentals

Company Overview: Lemonade, Inc. operates as a digital insurance provider across the United States and Europe, offering a diverse array of policies including renters, homeowners, pet, auto, life, and landlord insurance. The company functions on a digital substrate, leveraging AI (specifically "AI Maya") to automate underwriting and claims processing.

Key Business Metrics (as of Q1 2026 / FY2026 Guidance):

• Growth in Premium: In-force premium (IFP) reached $1.33 billion in Q1 2026, growing 32% year-over-year. Gross written premium increased 35% to $343.9 million for the three months ended March 31, 2026. Net earned premium surged 104% to $212.6 million in the same period.
• Customer Base: The company has passed 3 million customers. Notably, 1.9 million of these customers already hold car insurance, representing a significant cross-sell opportunity with near-zero acquisition costs.
• Product Milestones: Pet insurance (PE) has become the largest line of business, reaching a milestone of $500 million in IFP. Of the $85 million in current pet IFP, $85 million was sourced from the existing customer base, demonstrating strong retention and cross-selling efficacy.
• Operational Efficiency: As of December 31, 2025, roughly 55% of claims were automated, resulting in instant or near-instant processing.
• Reinsurance & Capital: The company renewed its reinsurance program with Hannover and MAPFRE effective July 1, 2025, with a reduced effective cession rate of 20% (normalized from higher rates in previous years). The company has $179.6 million of outstanding borrowings under an amended agreement, with an additional $200 million of financing available through December 31, 2026, for sales and marketing growth.

Management Expectations (Recorded as of April 2026):

• Profitability Path: Management reiterated the expectation that Q4 2026 will be EBITDA positive, and the full year of 2027 will be EBITDA positive.
• Expense Guidance: Q2 gross spend is expected to step up approximately 12% versus Q1, with total gross spend for the full year 2026 expected to be approximately $235 million.
• Ceding Rates: The seed rate (ceding rate) was approximately 30% in Q1, expected to ebb further in Q2, with a target normalization to 20% in Q3.

4. Archetype and Conviction Stack

Archetype: Growth Leader / Margin Inflector Lemonade fits the archetype of a high-growth insurtech transitioning toward profitability. The business model is shifting from pure customer acquisition to margin expansion via automation and cross-selling. The "margin inflector" aspect is evident in the management's guidance regarding the normalization of ceding rates (from 55% peak to 20% target) and the automation of 55% of claims, which directly impacts the loss ratio and operating leverage.

Valuation & Financial Spine:

• Forward Consensus EPS: FY1 is projected at -1.73, and FY2 at -0.82. The company is still in a pre-profitability phase, consistent with the "Growth Leader" archetype where valuation is driven by revenue growth and path to EBITDA rather than current earnings.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro tailwinds).
• Evidence Quality: High. Recent filings (E1-E27) provide robust, specific data on premium growth, customer retention, and operational efficiency.
• Rerating Potential: High, contingent on the successful execution of the Q4 2026 EBITDA positive guidance and the continued expansion of the pet and auto lines.

ATR Context: The current ATR of 6.0% falls into the "High" bucket (4–6% is the historical sweet spot, 6–8% is elevated). This suggests that while the setup is structurally sound, volatility will be significant, requiring careful position sizing.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental Deterioration: A significant deviation from the guidance of Q4 2026 EBITDA positivity, or a failure to maintain the 20% ceding rate target, would undermine the margin inflector thesis.

What Would Strengthen the Case:

• Fundamental Acceleration: Continued double-digit growth in in-force premium and successful cross-selling into the 1.9 million existing auto customers, validating the "multi-billion dollar opportunity" cited in filings.

Gaps in Evidence:

• No Named Secular Thesis: The lack of a broader macro thesis means the trade relies entirely on the company's execution and the technical setup, offering less downside protection if the broader market turns against growth stocks.
• Profitability Timeline: While management expects EBITDA positivity in Q4 2026, the exact path to profitability remains a forward-looking expectation rather than a realized historical fact as of this date.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: In-force premium grew 32% YoY to $1.33B; Pet insurance reached $500M IFP milestone; Management guidance for Q4 2026 EBITDA positivity; 55% of claims automated as of Dec 2025. Key risks: Price remains below breakout level of $99.90; Current ATR of 6.0% indicates high volatility; Company still reporting negative EPS with FY1 at -1.73; Dependence on successful execution of ceding rate normalization. Sizing hint: Position size should be reduced relative to confirmed breakouts due to the "forming" state and high ATR; treat as a partial allocation pending breakout confirmation. Expected horizon: 3 to 6 months, aligned with the Q4 2026 earnings cycle and the structural breakout requirement. Failure mode to watch: A daily close below $52.54, which would invalidate the forming coil structure and signal a breakdown in the technical setup.